• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Assisted reproductive technologies for male subfertility.针对男性生育力低下的辅助生殖技术。
Cochrane Database Syst Rev. 2016 Feb 26;2(2):CD000360. doi: 10.1002/14651858.CD000360.pub5.
2
Intra-uterine insemination for unexplained subfertility.不明原因的亚生育力的宫内人工授精。
Cochrane Database Syst Rev. 2016 Feb 19;2:CD001838. doi: 10.1002/14651858.CD001838.pub5.
3
Intra-uterine insemination for male subfertility.针对男性生育力低下的宫腔内人工授精。
Cochrane Database Syst Rev. 2007 Oct 17(4):CD000360. doi: 10.1002/14651858.CD000360.pub4.
4
Intra-uterine insemination for male subfertility.针对男性生育力低下的宫腔内人工授精。
Cochrane Database Syst Rev. 2007 Jul 18(3):CD000360. doi: 10.1002/14651858.CD000360.pub3.
5
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.重组促黄体生成素(rLH)和重组促卵泡生成素(rFSH)用于体外受精/卵胞浆内单精子注射周期中的卵巢刺激。
Cochrane Database Syst Rev. 2017 May 24;5(5):CD005070. doi: 10.1002/14651858.CD005070.pub3.
6
Intra-uterine insemination for unexplained subfertility.不明原因的亚生育力的宫内人工授精
Cochrane Database Syst Rev. 2012 Sep 12(9):CD001838. doi: 10.1002/14651858.CD001838.pub4.
7
Volume expanders for the prevention of ovarian hyperstimulation syndrome.用于预防卵巢过度刺激综合征的扩容剂。
Cochrane Database Syst Rev. 2016 Aug 31;2016(8):CD001302. doi: 10.1002/14651858.CD001302.pub3.
8
In vitro fertilisation for unexplained subfertility.不明原因的亚生育力的体外受精。
Cochrane Database Syst Rev. 2005 Apr 18(2):CD003357. doi: 10.1002/14651858.CD003357.pub2.
9
In vitro fertilisation for unexplained subfertility.不明原因不孕的体外受精。
Cochrane Database Syst Rev. 2023 Sep 27;9(9):CD003357. doi: 10.1002/14651858.CD003357.pub5.
10
Cycle regimens for frozen-thawed embryo transfer.冻融胚胎移植的周期方案。
Cochrane Database Syst Rev. 2017 Jul 5;7(7):CD003414. doi: 10.1002/14651858.CD003414.pub3.

引用本文的文献

1
Association between hypo-osmotic swelling test-induced tail swelling patterns and sperm quality.低渗肿胀试验诱导的尾部肿胀模式与精子质量之间的关联。
Future Sci OA. 2024 Dec 31;10(1):2410696. doi: 10.1080/20565623.2024.2410696. Epub 2024 Oct 17.
2
The effect of Chinese herbal medicine on male factor infertility: study protocol for a randomized controlled trial.中草药治疗男性因素不孕的效果:一项随机对照试验的研究方案。
Front Endocrinol (Lausanne). 2024 Jul 22;15:1418936. doi: 10.3389/fendo.2024.1418936. eCollection 2024.
3
Advanced Sperm Selection Techniques for Assisted Reproduction.辅助生殖的先进精子筛选技术
J Pers Med. 2024 Jul 4;14(7):726. doi: 10.3390/jpm14070726.
4
Effect of alternative and complementary medicine on male infertility: An umbrella review.替代医学和补充医学对男性不育症的影响:一项伞形综述。
Health Sci Rep. 2024 Jun 24;7(6):e2118. doi: 10.1002/hsr2.2118. eCollection 2024 Jun.
5
Spermbots and Their Applications in Assisted Reproduction: Current Progress and Future Perspectives.精子机器人及其在辅助生殖中的应用:当前进展和未来展望。
Int J Nanomedicine. 2024 May 31;19:5095-5108. doi: 10.2147/IJN.S465548. eCollection 2024.
6
From Diagnosis to Treatment: Comprehensive Care by Reproductive Urologists in Assisted Reproductive Technology.从诊断到治疗:辅助生殖技术中生殖泌尿科医生的综合护理。
Medicina (Kaunas). 2023 Oct 15;59(10):1835. doi: 10.3390/medicina59101835.
7
Correlation study of male semen parameters and embryo aneuploidy in preimplantation genetic testing for aneuploidy.植入前遗传学检测非整倍体中男性精液参数与胚胎非整倍体的相关性研究。
Front Endocrinol (Lausanne). 2023 Jan 26;13:1072176. doi: 10.3389/fendo.2022.1072176. eCollection 2022.
8
Comparison of Clinical Outcomes, Risks, and Costs for 20,910 Donor In Vitro Fertilization and 16,850 Donor Artificial Insemination Treatment Cycles: A Retrospective Analysis in China.20910个供体体外受精周期与16850个供体人工授精治疗周期的临床结局、风险及成本比较:中国的一项回顾性分析
J Clin Med. 2023 Jan 26;12(3):954. doi: 10.3390/jcm12030954.
9
Mesenchymal stem cells to treat female infertility; future perspective and challenges: A review.间充质干细胞治疗女性不孕症:未来展望与挑战:综述
Int J Reprod Biomed. 2022 Oct 10;20(9):709-722. doi: 10.18502/ijrm.v20i9.12061. eCollection 2022 Sep.
10
Sperm selection with hyaluronic acid improved live birth outcomes among older couples and was connected to sperm DNA quality, potentially affecting all treatment outcomes.使用透明质酸进行精子选择可改善高龄夫妇的活产结局,并与精子 DNA 质量有关,可能影响所有治疗结局。
Hum Reprod. 2022 May 30;37(6):1106-1125. doi: 10.1093/humrep/deac058.

本文引用的文献

1
Is IVF-served two different ways-more cost-effective than IUI with controlled ovarian hyperstimulation?试管婴儿服务有两种不同方式——比控制性卵巢过度刺激下的宫腔内人工授精更具成本效益吗?
Hum Reprod. 2015 Oct;30(10):2331-9. doi: 10.1093/humrep/dev193. Epub 2015 Aug 12.
2
Cost-effectiveness of assisted conception for male subfertility.男性不育症辅助受孕的成本效益
Reprod Biomed Online. 2015 Jun;30(6):659-66. doi: 10.1016/j.rbmo.2015.02.006. Epub 2015 Feb 24.
3
Total motile sperm count: a better indicator for the severity of male factor infertility than the WHO sperm classification system.总活动精子数:比世卫组织精子分类系统更能反映男性因素不育症严重程度的指标。
Hum Reprod. 2015 May;30(5):1110-21. doi: 10.1093/humrep/dev058. Epub 2015 Mar 18.
4
Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection.卵胞浆内单精子注射的使用趋势及相关生殖结局
JAMA. 2015 Jan 20;313(3):255-63. doi: 10.1001/jama.2014.17985.
5
Prevention of multiple pregnancies in couples with unexplained or mild male subfertility: randomised controlled trial of in vitro fertilisation with single embryo transfer or in vitro fertilisation in modified natural cycle compared with intrauterine insemination with controlled ovarian hyperstimulation.不明原因或轻度男性不育夫妇中多胎妊娠的预防:体外受精单胚胎移植或改良自然周期体外受精与控制性卵巢刺激宫腔内人工授精的随机对照试验。
BMJ. 2015 Jan 9;350:g7771. doi: 10.1136/bmj.g7771.
6
International Committee for Monitoring Assisted Reproductive Technologies world report: Assisted Reproductive Technology 2006.国际辅助生殖技术监测委员会世界报告:辅助生殖技术 2006 年报告。
Hum Reprod. 2014 Jul;29(7):1536-51. doi: 10.1093/humrep/deu084. Epub 2014 May 2.
7
Comparative analysis of three sperm DNA damage assays and sperm nuclear protein content in couples undergoing assisted reproduction treatment.接受辅助生殖治疗的夫妇中三种精子DNA损伤检测方法与精子核蛋白含量的比较分析。
Hum Reprod. 2014 May;29(5):904-17. doi: 10.1093/humrep/deu040. Epub 2014 Mar 10.
8
A randomised controlled trial of intra-uterine insemination versus in vitro fertilisation in patients with idiopathic or mild male infertility.一项针对特发性或轻度男性不育患者的宫内人工授精与体外受精的随机对照试验。
Aust N Z J Obstet Gynaecol. 2014 Apr;54(2):156-61. doi: 10.1111/ajo.12168. Epub 2014 Feb 28.
9
Comparison of the outcome of conventional in vitro fertilization and intracytoplasmic sperm injection in moderate male infertility from ejaculate.常规体外受精与卵胞浆内单精子注射治疗中度射精障碍男性不育症的疗效比较。
Urol Int. 2015;94(1):111-6. doi: 10.1159/000353975. Epub 2013 Nov 13.
10
International Committee for Monitoring Assisted Reproductive Technologies (ICMART) world report: assisted reproductive technology 2004.国际辅助生殖技术监测委员会(ICMART)世界报告:辅助生殖技术 2004 年报告。
Hum Reprod. 2013 May;28(5):1375-90. doi: 10.1093/humrep/det036. Epub 2013 Feb 26.

针对男性生育力低下的辅助生殖技术。

Assisted reproductive technologies for male subfertility.

作者信息

Cissen Maartje, Bensdorp Alexandra, Cohlen Ben J, Repping Sjoerd, de Bruin Jan Peter, van Wely Madelon

机构信息

Department of Obstetrics and Gynaecology, Jeroen Bosch Hospital, Henri Dunantstraat 1, PO Box 90153, 's-Hertogenbosch, Netherlands, 5200 ME.

出版信息

Cochrane Database Syst Rev. 2016 Feb 26;2(2):CD000360. doi: 10.1002/14651858.CD000360.pub5.

DOI:10.1002/14651858.CD000360.pub5
PMID:26915339
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10335364/
Abstract

BACKGROUND

Intra-uterine insemination (IUI), in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) are frequently used fertility treatments for couples with male subfertility. The use of these treatments has been subject of discussion. Knowledge on the effectiveness of fertility treatments for male subfertility with different grades of severity is limited. Possibly, couples are exposed to unnecessary or ineffective treatments on a large scale.

OBJECTIVES

To evaluate the effectiveness and safety of different fertility treatments (expectant management, timed intercourse (TI), IUI, IVF and ICSI) for couples whose subfertility appears to be due to abnormal sperm parameters.

SEARCH METHODS

We searched for all publications that described randomised controlled trials (RCTs) of the treatment for male subfertility. We searched the Cochrane Menstrual Disorders and Subfertility Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, PsycINFO and the National Research Register from inception to 14 April 2015, and web-based trial registers from January 1985 to April 2015. We applied no language restrictions. We checked all references in the identified trials and background papers and contacted authors to identify relevant published and unpublished data.

SELECTION CRITERIA

We included RCTs comparing different treatment options for male subfertility. These were expectant management, TI (with or without ovarian hyperstimulation (OH)), IUI (with or without OH), IVF and ICSI. We included only couples with abnormal sperm parameters.

DATA COLLECTION AND ANALYSIS

Two review authors independently selected the studies, extracted data and assessed risk of bias. They resolved disagreements by discussion with the rest of the review authors. We performed statistical analyses in accordance with the guidelines for statistical analysis developed by The Cochrane Collaboration. The quality of the evidence was rated using the GRADE methods. Primary outcomes were live birth and ovarian hyperstimulation syndrome (OHSS) per couple randomised.

MAIN RESULTS

The review included 10 RCTs (757 couples). The quality of the evidence was low or very low for all comparisons. The main limitations in the evidence were failure to describe study methods, serious imprecision and inconsistency. IUI versus TI (five RCTs)Two RCTs compared IUI with TI in natural cycles. There were no data on live birth or OHSS. We found no evidence of a difference in pregnancy rates (2 RCTs, 62 couples: odds ratio (OR) 4.57, 95% confidence interval (CI) 0.21 to 102, very low quality evidence; there were no events in one of the studies).Three RCTs compared IUI with TI both in cycles with OH. We found no evidence of a difference in live birth rates (1 RCT, 81 couples: OR 0.89, 95% CI 0.30 to 2.59; low quality evidence) or pregnancy rates (3 RCTs, 202 couples: OR 1.51, 95% CI 0.74 to 3.07; I(2) = 11%, very low quality evidence). One RCT reported data on OHSS. None of the 62 women had OHSS.One RCT compared IUI in cycles with OH with TI in natural cycles. We found no evidence of a difference in live birth rates (1 RCT, 44 couples: OR 3.14, 95% CI 0.12 to 81.35; very low quality evidence). Data on OHSS were not available. IUI in cycles with OH versus IUI in natural cycles (five RCTs)We found no evidence of a difference in live birth rates (3 RCTs, 346 couples: OR 1.34, 95% CI 0.77 to 2.33; I(2) = 0%, very low quality evidence) and pregnancy rates (4 RCTs, 399 couples: OR 1.68, 95% CI 1.00 to 2.82; I(2) = 0%, very low quality evidence). There were no data on OHSS. IVF versus IUI in natural cycles or cycles with OH (two RCTs)We found no evidence of a difference in live birth rates between IVF versus IUI in natural cycles (1 RCT, 53 couples: OR 0.77, 95% CI 0.25 to 2.35; low quality evidence) or IVF versus IUI in cycles with OH (2 RCTs, 86 couples: OR 1.03, 95% CI 0.43 to 2.45; I(2) = 0%, very low quality evidence). One RCT reported data on OHSS. None of the women had OHSS.Overall, we found no evidence of a difference between any of the groups in rates of live birth, pregnancy or adverse events (multiple pregnancy, miscarriage). However, most of the evidence was very low quality.There were no studies on IUI in natural cycles versus TI in stimulated cycles, IVF versus TI, ICSI versus TI, ICSI versus IUI (with OH) or ICSI versus IVF.

AUTHORS' CONCLUSIONS: We found insufficient evidence to determine whether there was any difference in safety and effectiveness between different treatments for male subfertility. More research is needed.

摘要

背景

宫腔内人工授精(IUI)、体外受精(IVF)和卵胞浆内单精子注射(ICSI)是治疗男性生育力低下夫妇常用的辅助生殖技术。这些技术的应用一直存在争议。目前对于不同严重程度男性生育力低下的治疗效果的了解有限。可能会导致夫妇在很大程度上接受了不必要或无效的治疗。

目的

评估不同辅助生殖技术(期待治疗、定时性交(TI)、IUI、IVF和ICSI)对因精子参数异常导致生育力低下夫妇的有效性和安全性。

检索方法

检索所有描述男性生育力低下治疗的随机对照试验(RCT)。检索Cochrane月经紊乱与生育力低下小组专业注册库、Cochrane对照试验中心注册库(CENTRAL)、MEDLINE、EMBASE、CINAHL、PsycINFO和国家研究注册库,检索时间从建库至2015年4月14日,并检索1985年1月至2015年4月的基于网络的试验注册库。检索无语言限制。检查纳入试验和背景文献中的所有参考文献,并联系作者以识别相关的已发表和未发表数据。

选择标准

纳入比较男性生育力低下不同治疗方案的RCT。这些方案包括期待治疗、TI(有或无卵巢过度刺激(OH))、IUI(有或无OH)、IVF和ICSI。仅纳入精子参数异常的夫妇。

数据收集与分析

两位综述作者独立选择研究、提取数据并评估偏倚风险。他们通过与其他综述作者讨论解决分歧。我们按照Cochrane协作网制定的统计分析指南进行统计分析。使用GRADE方法对证据质量进行评级。主要结局是每对随机分组夫妇的活产和卵巢过度刺激综合征(OHSS)。

主要结果

该综述纳入10项RCT(757对夫妇)。所有比较的证据质量均为低或极低。证据的主要局限性在于未描述研究方法、严重不精确和不一致。IUI与TI比较(5项RCT):两项RCT在自然周期中将IUI与TI进行比较。无活产或OHSS数据。我们未发现妊娠率有差异的证据(2项RCT,62对夫妇:比值比(OR)4.57,95%置信区间(CI)0.21至102,极低质量证据;其中一项研究无事件发生)。三项RCT在OH周期中将IUI与TI进行比较。我们未发现活产率有差异的证据(1项RCT,81对夫妇:OR 0.89,95%CI 0.30至2.59;低质量证据)或妊娠率有差异的证据(3项RCT,202对夫妇:OR 1.51,95%CI 0.74至3.07;I² = 11%,极低质量证据)。一项RCT报告了OHSS数据。62名女性中无一例发生OHSS。一项RCT将OH周期中的IUI与自然周期中的TI进行比较。我们未发现活产率有差异的证据(1项RCT,44对夫妇:OR 3.14,95%CI 0.12至81.35;极低质量证据)。无OHSS数据。OH周期中的IUI与自然周期中的IUI比较(5项RCT):我们未发现活产率(3项RCT,346对夫妇:OR 1.34,95%CI 0.77至2.33;I² = 0%,极低质量证据)和妊娠率(4项RCT,399对夫妇:OR 1.68,95%CI 1.00至2.82;I² = 0%,极低质量证据)有差异的证据。无OHSS数据。自然周期或OH周期中IVF与IUI比较(2项RCT):我们未发现自然周期中IVF与IUI活产率有差异的证据(1项RCT,53对夫妇:OR 0.77,95%CI 0.25至2.35;低质量证据),或OH周期中IVF与IUI活产率有差异的证据(2项RCT,86对夫妇:OR 1.03,95%CI 0.43至2.45;I² = 0%,极低质量证据)。一项RCT报告了OHSS数据。女性中无一例发生OHSS。总体而言,我们未发现任何组间在活产率、妊娠率或不良事件(多胎妊娠、流产)发生率上有差异的证据。然而,大多数证据质量极低。未对自然周期中的IUI与刺激周期中的TI、IVF与TI、ICSI与TI、ICSI与IUI(有OH)或ICSI与IVF进行研究。

作者结论

我们没有足够的证据来确定不同男性生育力低下治疗方法在安全性和有效性上是否存在差异。需要更多的研究。